WCN26-2146 PROTECT POST HOC ANALYSIS: EFFICACY OF SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IgA NEPHROPATHY ≤12 MO VS >12 MO FROM KIDNEY BIOPSY

Read full text Summarise with VIRAT
Authors: Jonathan Barratt, Radko Komers, Stephanie Moody, Alex Mercer, Vladimír Tesař, Shikha Wadhwani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sparsentan, a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), showed superior proteinuria reduction and kidney function preservation vs maximum labeled dose irbesartan in the phase 3, randomized, double-blind PROTECT trial. While sparsentan was favored across multiple prespecified subgroups, it is not known whether time from biopsy to informed consent affects efficacy.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105717–105717
Publication date
25 March 2026
Language
EN